Caspases: Therapeutic Targets in Neurologic Disease

被引:33
作者
Troy, Carol M. [1 ,2 ,3 ]
Jean, Ying Y. [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA
[2] Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10032 USA
[3] Columbia Univ, Med Ctr, Taub Inst Study Alzheimers Dis & Aging Brain, New York, NY 10032 USA
基金
美国国家卫生研究院;
关键词
Caspase; Inhibitor of apoptosis protein; Alzheimer's disease; Cerebral ischemia; Stroke; STRESS-INDUCED APOPTOSIS; ALZHEIMERS-DISEASE; CELL-DEATH; NLRP3; INFLAMMASOME; NERVOUS-SYSTEM; MESSENGER-RNA; ACTIVATION; EXPRESSION; INHIBITOR; CLEAVAGE;
D O I
10.1007/s13311-014-0307-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Specific therapies for neurologic diseases such as Alzheimer's disease provide the potential for better clinical outcomes. Expression of caspases in the brain is developmentally regulated, and dysregulated in neurologic disease, supporting that caspases may be therapeutic targets. The activity of caspases is carefully regulated via binding partners, cleavage, or endogenous inhibitors to prevent spontaneous activation, which could lead to aberrant cell death. This review serves as a brief examination of the current understanding of the regulation and function of caspases, and approaches to specifically target aberrant caspase activity. The use of proper tools to investigate individual caspases is addressed. Moreover, it summarizes the reports of various caspases in Alzheimer's disease studies. A better understanding of specific caspase pathways in heath and neurodegenerative disease is crucial for identifying specific targets for the development of therapeutic interventions.
引用
收藏
页码:42 / 48
页数:7
相关论文
共 50 条
  • [41] Rho GTPases as therapeutic targets in Alzheimer’s disease
    Byron J. Aguilar
    Yi Zhu
    Qun Lu
    Alzheimer's Research & Therapy, 9
  • [42] Rho GTPases as therapeutic targets in Alzheimer's disease
    Aguilar, Byron J.
    Zhu, Yi
    Lu, Qun
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [43] Nuclear receptors as therapeutic targets for Alzheimer's disease
    Mandrekar-Colucci, Shweta
    Landreth, Gary E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (09) : 1085 - 1097
  • [44] Are mitophagy enhancers therapeutic targets for Alzheimer's disease?
    Pradeepkiran, Jangampalli Adi
    Hindle, Ashly
    Kshirsagar, Sudhir
    Reddy, P. Hemachandra
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 149
  • [45] Protein palmitoylation: biological functions, disease, and therapeutic targets
    Qian, Yan-Ran
    Zhao, Yu-Jia
    Zhang, Feng
    MEDCOMM, 2025, 6 (03):
  • [46] Secretases as therapeutic targets for the treatment of Alzheimer's disease
    Dominguez, DI
    De Strooper, B
    Annaert, W
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2001, 8 (02): : 124 - 142
  • [47] Systemic Metabolism and Mitochondria in the Mechanism of Alzheimer's Disease: Finding Potential Therapeutic Targets
    Song, Meiying
    Fan, Xiang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [48] Depletion of Beclin-1 due to proteolytic cleavage by caspases in the Alzheimer's disease brain
    Rohn, Troy T.
    Wirawan, Ellen
    Brown, Raquel J.
    Harris, Jordan R.
    Masliah, Eliezer
    Vandenabeele, Peter
    NEUROBIOLOGY OF DISEASE, 2011, 43 (01) : 68 - 78
  • [49] Acid-sensing ion channels: potential therapeutic targets for neurologic diseases
    Liu, Sha
    Cheng, Xiao-Yu
    Wang, Fen
    Liu, Chun-Feng
    TRANSLATIONAL NEURODEGENERATION, 2015, 4
  • [50] The mitochondrial permeability transition in neurologic disease
    Norenberg, M. D.
    Rao, K. V. Rama
    NEUROCHEMISTRY INTERNATIONAL, 2007, 50 (7-8) : 983 - 997